Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical hodgkins lymphoma (HL)

Klinische Padiatrie

Volumn 224, Issue 6, 2012, Pages 377-381

  Haase, R ^a   Vilser, C ^a   Mauz Korholz C ^a   Hasenclever, D ^b   Kluge, R ^c   Ruschke, K ^a   Borkhardt, A ^d   Seeger, K ^e   Lehrnbecher, T ^f   Kulozik, A ^g   Rossler J ^h   Burdach, S ⁱ   Jurgens H ^j   Korholz D ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

more..

Author keywords

c reactive protein; GPOH HD 2002 study; hodgkins lymphoma; prognosis; risk factor

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHILD; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONSET AGE; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SURVIVAL TIME; SYMPTOM;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84869086308     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1323824     Document Type: Article

References (34)

1. Axdorph U., Sjoberg J., Grimfors G. et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkins disease. Ann Oncol: 2000; 11 1405 1411
2. Bien E., Balcerska A. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkins lymphoma. Scand J Immunol: 2009; 70 490 500
3. Bien E., Balcerska A., Adamkiewicz-Drozynska E. et al. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkins lymphomas and acute lymphoblastic leukemias. Clin Biochem: 2009; 42 1144 1157
4. Carbone P. P., Kaplan H. S., Musshoff K. et al. Report of the Committee on Hodgkins Disease Staging Classification. Cancer Res: 1971; 31 1860 1861
5. Child J. A., Spati B., Illingworth S. et al. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients. Cancer: 1980; 45 318 326 (Pubitemid 10212198)
6. Debling D., Spix C., Blettner M. et al. The cohort of long-term survivors at the German childhood cancer registry. Klin Padiatr: 2008; 220 371 377
7. Dorffel W., Luders H., Ruhl U. et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkins disease in children and adolescents: analysis and outlook. Klin Padiatr: 2003; 215 139 145 (Pubitemid 36718285)
8. Fischer M., Bijman M., Molin D. et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkins lymphoma. Leukemia: 2003; 17 2513 2516 (Pubitemid 38072592)
9. Funovics P. T., Edelhauser G., Funovics M. A. et al. Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop: 2011; 35 1529 1536
10. Garcia R., Hernandez J. M., Caballero M. D. et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkins disease. Br J Cancer: 1993; 68 1227 1231 (Pubitemid 23356681)
11. Gause A., Roschansky V., Tschiersch A. et al. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkins lymphoma. Ann Oncol: 1991; 2 02 43 47
12. Han Y., Mao F., Wu Y. et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers: 2011; 26 209 215
13. Hasenclever D. The disappearance of prognostic factors in Hodgkins disease. Ann Oncol: 2002; 13 01 75 78 (Pubitemid 34567405)
14. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkins disease. International Prognostic Factors Project on Advanced Hodgkins Disease. N Engl J Med: 1998; 339 1506 1514
15. Heikkila K., Ebrahim S., Lawlor D. A. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health: 2007; 61 824 833
16. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J: 1990; 265 621 636 (Pubitemid 20053863)
17. Hong S., Kang Y. A., Cho B. C. et al. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J: 2012; 53 111 117
18. Kelley T. W., Pohlman B., Elson P. et al. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol: 2007; 128 958 965
19. Kelly K. M. Management of children with high-risk Hodgkin lymphoma. Br J Haematol: 2012; 157 3 13
20. Khandavilli S. D., Ceallaigh P. O., Lloyd C. J. et al. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol: 2009; 45 912 914
21. Klimm B., Engert A. Combined modality treatment of Hodgkins lymphoma. Cancer J: 2009; 15 143 149
22. Kluge R., Korholz D. Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klin Padiatr: 2011; 223 315 319
23. Kurzrock R., Redman J., Cabanillas F. et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkins disease and with B symptoms. Cancer Res: 1993; 53 2118 2122 (Pubitemid 23145736)
24. Lawrenz B., Henes M., Neunhoeffer E. et al. Fertility preservation in girls and adolescents before chemotherapy and radiation - review of the literature. Klin Padiatr: 2011; 223 126 130
25. Legouffe E., Rodriguez C., Picot M. C. et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkins lymphoma. Leuk Lymphoma: 1998; 31 351 357 (Pubitemid 29033956)
26. Mauz-Korholz C., Hasenclever D., Dorffel W. et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkins lymphoma: the GPOH-HD-2002 study. J Clin Oncol: 2010; 28 3680 3686
27. Nakamura T., Matsumine A., Matsubara T. et al. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer: 2012; 118 1055 1061
28. Nozoe T., Saeki H., Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg: 2001; 182 197 201 (Pubitemid 32907362)
29. Saito K., Kihara K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther: 2010; 10 1979 1989
30. Saito K., Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol: 2011; 8 659 666
31. Steidl C., Lee T., Shah S. P. et al. Tumor-associated macrophages and survival in classic Hodgkins lymphoma. N Engl J Med: 2010; 362 875 885
32. von Tresckow B., Plutschow A., Fuchs M. et al. Dose-Intensification in Early Unfavorable Hodgkins Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol: 2012; 30 907 913
33. Wieland A., Kerbl R., Berghold A. et al. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol: 2003; 41 21 25 (Pubitemid 41103249)
34. Zielinski C. C., Preis P., Aiginger P. et al. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkins disease. J Cancer Res Clin Oncol: 1985; 110 65 70 (Pubitemid 15030765)